Accuray Incorporated (ARAY) revealed that its new CyberKnife M6 Series and TomoTherapy H Series Systems are steadily gaining market share worldwide. This announcement was made by the company at the 55th Annual American Society for Radiation Oncology (:ASTRO) meeting being held at the Georgia World Congress Center in Atlanta.
The two new treatment platforms were launched by ARAY last year. Knowledge on the clinical capabilities on the same can be derived through presentations to be delivered by leading radiation oncology practitioners during the ASTRO meeting.
ARAY informed that many cancer centers in the U.S. as well as in Europe have already invested in the technology, contributing to the consistent adoption and growth of the company’s advanced line of products.
Some of the U.S. centers that have started to invest in such new age product platforms include the University of Pittsburgh Medical Center and Lancaster General Health in PA, Tulsa Cancer Institute of Oklahoma, Spokane CyberKnife & Radiation Oncology Center in Wash and University of Arkansas Medical Sciences in Little Rock, AR.
Centers in Europe and Asia include, the European CyberKnife Center Munich-Grosshadern (:ECZM) in Munich, and Heidelberg University Hospital in Germany. Erasmus Medical Center (:MC), in Rotterdam, the Netherlands; the Centre Oscar Lambret in Lille France; and The Severance Hospital, Yonsei University Healthcare System in Seoul, Korea.
Healthcare experts at the Barshinger Cancer Institute of Lancaster General Health in Pennsylvania have welcomed the new CyberKnife M6 System as its unique non-coplanar beam geometry helps to create high-quality, high-dose distributions. This guarantees high accuracy levels and minimizes side effects, thus improving and retaining the quality of patient’s lives.
They are keen about providing the most effective and efficient SRS/SBRT treatment option and believe that they can benefit from the CyberKnife System which can track and treat moving targets without affecting nearby critical structures and healthy tissue.
Experts at the Centre Oscar Lambret, Lille, France note that within the first three months of clinical use of the TomoHDA System at their center, they have achieved significant results. Rapid treatment planning and high-precision dose delivery are characteristics that are well compatible for treatment of breast cancer and helps improve overall quality, patient throughput and workflow for the department.
ARAY seeks to provide better and advanced treatment services to patients and continuously tries to enhance the capabilities of the TomoTherapy and CyberKnife Systems. In this regard, ARAY values the feedback received from leading radiation oncology practitioners who have collaborated with the company and relies on such positive relationships to build their product portfolio going forward.
Currently, ARAY carries a Zacks Rank #3 (Hold). Other stocks in the medical instrument industry include Cynosure, Inc. (CYNO) Delcath Systems, Inc. (DCTH), and Echo Therapeutics, Inc. (ECTE), each of which carries a Zacks Rank #2 (Buy).